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Prevalence of visual 
impairment
Changing demography 
When the Community Eye Health Journal 
was launched in 1988, the world population 
was approximately 5.1 billion. Over the last
20 years, it has increased by approximately 
30%, reaching 6.7 billion in 2008. During 
the same period, the world population has 
also become proportionally older, as the 
number of people aged 65 years and over 
has increased by approximately 55%, from 
320 million in 1988 to 500 million in 2008. 
Since the prevalence of visual impairment 
becomes higher as people age, this combi-
nation of an increasing population and an 
ageing population is expected to cause a 
signifi  cant increase in the total number of 
blind people.1
Estimates of the number of people 
with visual impairment worldwide
In 1988, the number of people who were blind 
(visual acuity (VA)  <3/60 in the better eye) 
was estimated to be 37 million worldwide. 
By 2002–04, the latest period for which we 
have data (see Table 1), it was estimated to 
be 45 million: 8 million blind due to uncor-
rected refractive error and 37 million blind 
due to other causes.2, 3 It is thought that at 
least 60% of blind people are women.
Little was known in 1988 about the 
prevalence of low vision (VA <6/18 to 3/60). 
In 2002, the number of people with low vision 
was estimated to be 124 million worldwide, 
but this excluded low vision due to refractive 
error.2 Owing to a lack of data from surveys, 
it has only very recently become possible to 
estimate that there are 145 million people 
with low vision due to refractive error.3
This fi  gure brings the overall number of 
people with low vision to 269 million.
In total, the number of people with visual 
impairment (which includes both low vision 
and blindness) is therefore estimated to be 
314 million worldwide.
Causes of blindness
Over the last twenty years, the causes of 
blindness have changed in proportion and 
actual number. Cataract has remained the 
major cause of blindness globally. It is partic-
ularly important in Asia. The numbers of people 
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Deﬁ  nition number of 
people (millions)
Blindness (eye disease)  <3/60 to no light perception 37
Blindness (refractive error)  <3/60 to light perception   8
Blindness (all causes) 45
Low vision (eye disease)  <6/18 to 3/60   124
Low vision (refractive error)  <6/18 to 3/60   145
Low vision (all causes) 269
Total: Visual impairment (all causes) 314
Table 1. Most recent estimates of the number of people with visual impairment
(blindness and low vision) worldwide2,3,4
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blinded by trachoma, onchocerciasis, and 
vitamin A deficiency have tended to decrease 
over the last twenty years. This is due to 
improvements in nutrition, water supplies, 
sanitation, and measles immunisation coverage, 
as well as to the provision of certain therapeutic 
medicines: ivermectin (Mectizan®), vitamin A, 
and antibiotics. Figure 1 shows the proportion 
of cases of blindness due to each major cause, 
according to the most recent estimates.
Cataract
Over the past twenty years, the major 
advance in the treatment of cataract has 
been the worldwide availability of low-cost, 
good-quality intraocular lenses (IOLs) since 
the early 1990s. Their routine use has 
resulted in an increase in both the quality of 
visual outcome for patients (as shown by 
population-based rapid assessment of 
cataract surgical services)5 and the willingness 
of surgeons to perform cataract surgery at 
an earlier time, before blindness has developed. 
This is detailed in the article on page 40. 
There is evidence that, since the intro-
duction of IOLs, there has been an increase 
in cataract surgical rates around the world, 
and particularly in low-income countries.4
Two other important developments in the 
past twenty years have been the populari-
sation of phacoemulsification and the 
introduction of small incision cataract surgery 
(SICS). Both have resulted in a faster and 
better restoration of visual acuity. With SICS, in 
addition, the cost per operation is also lower. 
Although it is difficult to obtain accurate 
figures, it is likely that the global number of 
cataract operations has increased from 
about 5 million per year in 1988 to around 
15 million per year now.
Despite these overall positive develop-
ments, we should not be complacent: 
17 million people are blind today because 
they have not yet received cataract surgery. 
Trachoma
In 1988, it was estimated that 150 million 
children were infected; this number had 
fallen to approximately 84 million by 2004.6 
Similarly, the number of people blind from 
trachoma decreased from approximately 
5 million in 1988 to 1.3 million in 2002.
 The SAFE strategy for trachoma control 
has become widely accepted, tarsal rotation 
has been shown to be the preferred 
surgical procedure for trichiasis, and 
oral azithromycin has become the 
first-choice antibiotic for mass 
treatment of communities with 
endemic trachoma infection (as 
shown in the article on page 43). It is 
also highly likely that improvements 
in water supply and sanitation have 
significantly reduced the transmission 
of trachoma infection in poor rural 
communities in Africa and Asia. However, 
more investigative work is required in order 
to reduce recurrence after trichiasis surgery 
and to identify the most cost-effective 
strategies for the distribution of azithromycin. 
Onchocerciasis
In 1988, onchocerciasis was a significant 
cause of blindness in many countries in Africa. 
This same year, however, saw important 
developments in the treatment of the disease: 
Merck & Co. had registered the microfilaricide 
ivermectin (Mectizan®) a year earlier and its 
Mectizan® Donation Programme came into 
effect, providing Mectizan® free of charge 
to individuals and communities with 
onchocerciasis, as shown in the article on 
page 43. Twenty years on, the severity of 
onchocerciasis infection is decreasing and 
the number of people developing vision loss 
has markedly decreased. The figures for 
2007 indicate that over 50 million people 
are now receiving Mectizan® on an annual 
basis through community-directed 
treatment  programmes. 
Childhood blindness
Although vitamin A deficiency was a well-
recognised cause of blindness in children 
twenty years ago, little work had been done 
up to that time on the magnitude and causes 
of childhood blindness. The article on page 46 
presents an overview of the data collected and 
the lessons learnt over the past twenty years.
These data show marked variations 
according to the socio-economic status of 
the community. For example, vitamin A 
deficiency still occurs in children under five 
years old living in very poor families and, today, 
rising food prices worldwide may aggravate 
this situation further. Similarly, retinopathy of 
prematurity has emerged as a significant 
problem in middle-income countries and in 
urban centres of the developing world. The 
most important treatable cause of childhood 
blindness, however, remains untreated or 
poorly treated cataract, which is responsible 
for 5–20% of all cases. 
Refractive error
Little was known in 1988 about the magnitude 
of visual loss due to refractive error. This 
was due to the fact that the World Health 
Organization’s (WHO) definition of blindness 
Glaucoma
10% 4.5m
AMD
7% 3.2m
Corneal scar
4% 1.9m
Diab. retinopathy
4% 1.8m
Childhood
3% 1.4m
Trachoma
3% 1.3m Oncho.
0.7% 0.3m
Other causes
11% 4.8m
Refractive error
18% 8m
Figure 1. Proportion of cases of blindness 
due to each major cause*
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was therefore not recorded in surveys. 
Since then, some population-based 
blindness surveys have included people who 
cannot see because they have no spectacles 
and specific surveys have been done to 
assess refractive error in school children. 
Figures published in 2008 indicate that, due 
to uncorrected refractive error, there are 
145 million people with VA ranging from 
<6/18 to 3/60 and 8 million people who are 
blind (VA <3/60) (see Table 1).3 Spectacles 
have generally become more available and 
more affordable, but in many countries there 
is still a need for good refraction services 
and for appropriate dispensing of low-cost 
but good-quality spectacles.
Glaucoma
During the last twenty years, work has been 
undertaken to develop improved definitions 
and classifications of glaucoma. This has 
allowed for better estimates to be made of 
the number of people with this condition.7 
It is likely that the current global estimate of 
4.5 million people blind due to glaucoma 
actually falls short of the true figure, as many 
surveys do not include an assessment of 
visual field loss and are limited to a definition 
of blindness based only on visual acuity. 
Globally, 60 million people are likely to have 
one of the glaucomas and up to 8 million 
may be blind because of this disease.
Because no simple, specific, and sensitive 
test exists for this condition, population-based 
screening cannot at present be advocated; 
opportunistic case detection should, 
however, be encouraged. Unfortunately, in 
many low- and middle-income countries, 
effective treatment for glaucoma is still out 
of reach: medical treatment requires the 
availability of affordable drugs and long-term 
patient compliance; surgical treatment 
requires patient acceptance, as well as 
surgical skill, experience, and the capacity 
for long-term follow-up. This is difficult to 
achieve in some settings.
Diabetic retinopathy
In 1988, there were no data on the global 
prevalence of diabetic retinopathy or of 
blindness resulting from this condition. It is 
now estimated that there are approximately 
171 million people with diabetes worldwide. 
Of these people, probably 10–20% have some 
form of retinopathy and around 1.78 million 
are blind. There are now better-defined 
screening procedures and agreed treatment 
protocols based upon evidence from clinical 
trials. In appropriate settings, therefore, 
there can now be a public health approach 
to the control of visual loss from diabetes.8
Age-related macular degeneration 
(AMD)
As life expectancy increases, AMD is 
becoming a more important problem, not 
only in high-income, but also in middle-
income countries (see article on page 48). 
In 2002, it was estimated that 3.2 million 
people were blind from AMD. As yet, there is 
no proven prevention for AMD although 
smoking has been shown to be an important 
risk factor. Various surgical procedures are 
being tried in selected cases and recent 
studies indicate that vascular endothelial 
growth factor (VEGF) blockers can delay or 
stop progression of vascular AMD (see 
article on page 50). In spite of promising 
recent developments, there is, however, no 
proven therapy to reverse the degenerative 
process in all cases and current therapies 
remain expensive.9
 
Making a difference with 
VISION 2020: The Right to 
Sight
In 1988, the WHO Prevention of Blindness 
(PBL) programme and the International 
Agency for the Prevention of Blindness 
(IAPB) had been in existence for ten years. 
Over the next decade, several important 
developments made it possible to conceive 
of a global initiative to eliminate avoidable 
blindness: the Mectizan® Donation 
Programme was established in 1987, 
low-cost IOLs became available in the early 
1990s, and the SAFE strategy was launched 
in 1996. In addition, the relationship 
between vitamin A deficiency and childhood 
mortality had already been documented. 
Drawing on their experiences of cost-
effective eye care delivery systems in several 
countries in the 1980s and 1990s, including 
in India and The Gambia, a group of non- 
governmental development organisations 
(NGDOs), together with the WHO, launched 
VISION 2020: The Right to Sight in 1999. 
This is a global initiative to eliminate 
avoidable blindness from cataract, 
trachoma, onchocerciasis, refractive error, 
vitamin A deficiency, and other causes of 
blindness in children by the year 2020. 
The World Health Assembly has since 
adopted resolutions urging its member 
states to adopt the VISION 2020 principles. 
More than 90 NGDOs, agencies, and 
institutions, together with a number of 
major corporations, are now working 
together in this global partnership. 
There is little doubt that the VISION 2020 
initiative has raised awareness concerning 
blindness and the cost-effectiveness of 
available interventions. It has mobilised 
both government and private funding for eye 
care and it has generated a global public-
private partnership working with a clearly 
defined focus and strategy. 
Estimates of global blindness made 
in 2002 were 15 million lower than the 
projections made for this same year when 
VISION 2020 was launched. There is also 
evidence that the number of people who are 
blind due to onchocerciasis and trachoma 
has decreased, as well as evidence of 
increasing cataract surgical rates in many 
countries. Our challenge now is to build on 
what has been achieved and to focus 
resources on the poorest communities in 
the world. The goal of VISION 2020 is to 
enable all persons to receive eye care and 
have the right to sight – which is one of their 
fundamental human rights. 
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